目的:最近的研究表明,富血小板纤维蛋白(PRF)是氨苄西林/舒巴坦的合适载体。研究的目的是研究PRF是否也是克林霉素(CLI)的合适生物载体。
方法:PRF膜来自36名接受CLI静脉治疗的患者(例如,由于诊断为颌骨坏死或感染)。用液相色谱-串联质谱法测定PRF膜中CLI的浓度,用新鲜的PRF和PRF储存24小时,在琼脂扩散试验中研究了抗菌作用。在36°C的培养箱中进行储存以模拟体内情况。
结果:血浆中CLI的平均浓度为1.0±0.3μg/100mg血浆;所得PRF膜为0.7±0.4μg/100mgPRF。用金黄色葡萄球菌进行琼脂扩散试验,肺炎链球菌,米炎链球菌,牙龈卟啉单胞菌,和具核梭杆菌.平均抑制区,mm,对于新的PRF,存储的PRF分别为17.3、12.2、18.8、17.1、25.8和18.1、12.7、19.2、17.3和26.3,分别。
结论:结果表明,当系统给予患者时,PRF是用于CLI的合适的生物载体。在输注600mgCLI剂量后从患者产生的PRF中的浓度足以靶向临床相关细菌。
结论:使用PRF作为局部应用抗生素的载体可以预防口腔颌面外科的感染。在研究限制范围内,通过将CLI作为一种新的抗生素加入到PRF治疗中,这一发现可以扩大PRF的应用范围.
OBJECTIVE: Recent research has demonstrated that platelet-rich fibrin (PRF) is an appropriate carrier for ampicillin/sulbactam. The aim of the study was to investigate whether PRF is also a suitable bio-carrier for clindamycin (CLI).
METHODS: PRF membranes were produced from 36 patients receiving intravenous therapy with CLI (e.g. due to the diagnosis of an osteonecrosis of the jaw or infections). Concentrations of CLI in PRF membranes were measured with liquid chromatography-tandem mass spectrometry, and the antimicrobial effects were investigated in vitro in agar diffusion tests with fresh PRF and PRF stored for 24 h. Storage was performed in an incubator at 36 °C to simulate the in-vivo situation.
RESULTS: The mean concentration of CLI in plasma was 1.0 ± 0.3 μg/100 mg plasma; in resulting PRF membranes 0.7 ± 0.4 μg/100 mg PRF. Agar diffusion tests were performed with Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus mitis, Porphyromonas gingivalis, and Fusobacterium nucleatum. Mean inhibition zones, in mm, for fresh PRF were 17.3, 12.2, 18.8, 17.1, 25.8 and 18.1, 12.7, 19.2, 17.3, and 26.3 for stored PRF, respectively.
CONCLUSIONS: The results demonstrate that PRF is a suitable bio-carrier for CLI when administered systemically to patients. The concentration in PRF generated from patients after infusion of 600 mg CLI dose suffices to target clinically relevant bacteria.
CONCLUSIONS: Using PRF as a carrier for local antibiotic application can prevent infections in oral and maxillofacial surgery. Within the study limitations, the findings could expand the scope of PRF application by adding CLI as a new antibiotic to the spectrum of PRF therapy.